Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Paragon Care Ltd.    PGC   AU000000PGC4

PARAGON CARE LTD.

(PGC)
  Report  
End-of-day quote. End-of-day quote AUSTRALIAN SECURITIES EXCHANGE LIMITED - 04/18
0.45 AUD   +2.27%
03/26PARAGON CARE : Securities Trading Policy (MAR2019)
PU
03/21PARAGON CARE : Notification of Dividend Distribution (MAR2019)
PU
03/21PARAGON CARE : Dividend Reinvestment Plan Issue Price (MAR2019)
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Paragon Care : Company Update & Earnings Outlook (FEB2019)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 06:15pm EDT

ASX ANNOUNCEMENT paragoncare.com.au

12th February 2019

Australian Securities Exchange Company Announcements Office

COMPANY UPDATE & EARNINGS OUTLOOK

Paragon Care Limited (ASX: PGC) ("Paragon" or the "Company") today announces preliminary results for the half year ending 31 December 2018 (1H19) and outlook for the 2019 financial year (FY19).

1H19 Preliminary results

Paragon will release its financial information for 1H19 to the market on or around 26th February 2019. Whilst the financials are still being finalised, the Company expects to report the following results:

Continuing business (excl. Discontinued)

Discontinued business1 & nonrecurring costs

1H19 Revenue

$119m

$11m

1H19 Gross Profit Margin

38%

37%

1H19 EBITDA

$14m2

$5m

Reflects planned sale of legacy capital equipment businesses

1)

2) Includes a A$1.8m positive benefit of AASB 16 (lease adjustment).

FY19 Outlook

The continuing business is performing at or above expectations and expected to generate revenues of approximately $240m and EBITDA of $28m in FY19 (including the $4m benefit from lease adjustment).

The Company is very pleased with sales growth and a stabilised gross profit margin during the first half, with organic growth now tracking at 9% from the continuing business. The strong organic growth reflects improved sales performance following actions in 2018 to strengthen sales leadership, transform sales culture and improve accountability. Paragon's 1H19 results will be negatively impacted by the legacy capital equipment business, which has not performed as profitably as expected, and delays with MIDAS business development.

At the 1H19 results the Company will provide revenue, gross profit and growth details for the following business areas: Devices, Diagnostics, Capital & Consumables; and Services & Technology.

The Company's performance for 1H19 and outlook is influenced by:

  • Strong organic growth - 9% from Continuing Businesses;

  • The discontinued business (legacy capital equipment) having not returned to the level of profitability as planned;

  • Continuing business now on track to integrate 70% of activities onto a single IT/ERP platform by 1 July 2019 and 100% by 31st December 2019;

  • The benefits of integration will start to flow from 1st July 2019. Cost reductions in FY20 are expected to be greater than $3m;

  • Strengthened sales leadership team and improved accountability has resulted in a strong sales pipeline;

  • Due diligence on the sale of the discontinued business is progressing well;

  • A change program driving revenue synergies and productivity in support services.

Management is focussed on maintaining the strong organic sales growth and firmly executing on the change program.

Paragon Care Limited - ABN 76 064 551 426

Registered Office: 11 Dalmore Drive, Scoresby, Victoria 3179

1

Tel (03) 1300 369 559. Fax (03) 8833 7890

ASX ANNOUNCEMENT paragoncare.com.au

Contacts

Andrew Just

Chief Executive Officer & Managing Director Tel. 1300 369 559

Email:andrew.just@paragoncare.com.au

About Paragon Care Limited

Paragon Care (ASX:PGC) is an Australian based listed company and a leading provider of medical equipment, devices and consumables for the Australian and New Zealand market. This is a high growth market driven by the ageing of the population, continuously rising consumer expectations and increasing government spending. Paragon Care has positioned itself to provide advanced technology solutions yielding recurring revenue streams in acute and ancillary care environments.

Paragon Care Limited - ABN 76 064 551 426

Registered Office: 11 Dalmore Drive, Scoresby, Victoria 3179

2

Tel (03) 1300 369 559. Fax (03) 8833 7890

Disclaimer

Paragon Care Ltd. published this content on 12 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 February 2019 23:14:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PARAGON CARE LTD.
03/26PARAGON CARE : Securities Trading Policy (MAR2019)
PU
03/21PARAGON CARE : Notification of Dividend Distribution (MAR2019)
PU
03/21PARAGON CARE : Dividend Reinvestment Plan Issue Price (MAR2019)
PU
03/21PARAGON CARE LTD. : Ex-dividend day for interim dividend
FA
03/12PARAGON CARE : Appendix 3X Initial Director's Interest Notice (MAR2019)
PU
03/12PARAGON CARE : Non-Executive Director Appointment (MAR2019)
PU
02/27PARAGON CARE : FY19 Half Year Results Presentation (FEB2018)
PU
02/27PARAGON CARE : Dividend Distribution Notification (FEB2019)
PU
02/27PARAGON CARE : Appendix 4D & Half Year Report (FEB2019)
PU
02/27PARAGON CARE : 1H19 Results (FEB2019)
PU
More news
Financials (AUD)
Sales 2019 251 M
EBIT 2019 20,9 M
Net income 2019 9,00 M
Debt 2019 -
Yield 2019 6,78%
P/E ratio 2019 15,00
P/E ratio 2020 9,00
Capi. / Sales 2019 0,61x
Capi. / Sales 2020 0,59x
Capitalization 152 M
Chart PARAGON CARE LTD.
Duration : Period :
Paragon Care Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PARAGON CARE LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 0,52  AUD
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Andrew Just Chief Executive Officer
Shane Francis Tanner Non-Executive Chairman
Michael G. Rice Chief Operating Officer
Len Kocovic Chief Financial Officer & Co-Secretary
Michael C. Newton Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PARAGON CARE LTD.-29.69%109
MEDTRONIC PLC-7.41%112 952
BAXTER INTERNATIONAL INC.12.93%37 991
HOYA CORPORATION15.32%25 377
ZIMMER BIOMET HOLDINGS15.70%24 550
ALIGN TECHNOLOGY34.41%22 518